Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

Christopher P Fox; William Townsend; John G Gribben; Tobias Menne; Nagesh Kalakonda; Paula Williams; Farah Toron; Emma Tyas; Miranda Cooper; Joshua Rickards; John Radford

doi:10.1002/jha2.970

Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

EJHaem. 2024 Aug 7;5(5):992-997. doi: 10.1002/jha2.970. eCollection 2024 Oct.

Authors

Affiliations

¹ School of Medicine University of Nottingham Nottingham UK.
² University College London Hospitals NHS Foundation Trust London UK.
³ Barts Cancer Institute Barts Health NHS Trust London UK.
⁴ Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK.
⁵ Molecular & Clinical Cancer Medicine University of Liverpool Liverpool UK.
⁶ Bristol Myers Squibb Uxbridge UK.
⁷ Lumanity Farnham UK.
⁸ Manchester Academic Health Science Centre The Christie NHS Foundation Trust and University of Manchester Manchester UK.

Abstract

Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

Keywords: ASCT; LBCL; outcomes; real‐world evidence.